Table 3 Hospital treatment, medication used for SE treatment, and tumor treatments prior to and during SE, stratified by tumor categories and tumor progression signs

All Cases

208(100)

116 (55.8)

30 (14.4)

53 (25.5)

128 (61.5)

80 (38.5)

Hospital treatment

Length of hospital stay (days)

 Mean ± SD

14.8 ± 11.5

14.7 ± 11.2

17.3 ± 11.7

12.8 ± 11.1

n.s

14.3 ± 10.8

15.4 ± 12.5

n.s

 Median (Range)

12 (1–57)

12 (1–49)

15 (3–45)

10 (1–37)

12 (1–57)

12(1–49)

ICU /IMC treatment

171 (82.2)

90 (77.6)

25 (83.3)

48 (90.6)

109 (85.2)

62 (77.5)

 Mean ± SD

8.9 ± 9.8

8.5 ± 10

12.2 ± 8.8

7.31 ± 8.7

&0.022; #0.005; §n.s

8.4 ± 9.5

9.7 ± 10.3

n.s

 Median (Range)

5.0 (1–46)

4 (1–46)

11 (1–31)

3.5 (1–37)

4 (1–46)

5 (1–41)

Mechanical ventilation

44 (21.2)

19 (16.4)

11 (36.7)

12 (22.6)

&0.003; #n.s.; §n.s

28 (21.9)

16 (20)

n.s

 For SE treatment

29 (13.9)

12 (10.3)

7 (23.3)

9 (17)

17 (13.3)

12 (15)

 For airway protection

15 (7.2)

7 (6)

4 (13.3)

3 (5.7)

11 (8.6)

4 (5)

Limitation of therapy during SE

36 (17.3)

21 (18.1)

2 (6.7)

12 (22.6)

n.s

29 (22.7)

7 (8.8)

0.009

Medication

 ASM use prior SE

126 (60.6)

84 (72.4)

13 (43.3)

24 (45.3)

&0.006; #n.s.; §0.001

72 (56.3)

54 (67.5)

n.s

 Mean number ± SD

1.6 ± 0.8

1.7 ± 0.9

1.5 ± 0.8

1.3 ± 0.5

n.s

1.5 ± 0.8

1.7 ± 0.8

n.s

 Median number (Range)

1 (1–5)

1 (1–5)

1 (1–3)

1 (1–3)

1 (1–5)

1 (1–5)

Number of ASMs used during SE

 Mean ± SD

3.6 ± 2.2

3.5 ± 2.1

3.6 ± 2.3

3.6 ± 2.5

n.s

3.6 ± 2.1

3.5 ± 2.4

n.s

 Median (Range)

3 (1–10)

3(1–9)

3 (1–9)

3(1–10)

3 (1–10)

3(1–10)

Number of ASMs at discharge

 Mean ± SD

2.2 ± 1.1

2.4 ± 1.1

2 ± 1

2 ± 1.1

n.s

2.1 ± 1

2.3 ± 1.2

n.s

 Median (Range)

2 (1–5)

2 (1–5)

2 (1–5)

2 (1–4)

2 (1–5)

2 (1–5)

Dexamethasone use at admission

64 (30.8)

43 (37)

2 (6.7)

18 (34)

& < 0.001; #0.002; §n.s

37 (28.9)

27 (33.8)

n.s

 Mean ± SD dosage (mg)

6.4 ± 5.9

6.5 ± 6.2

5.5 ± 5

5.8 ± 5.4

7 ± 6.7

4.6 ± 2.3

 Median (Range) dosage (mg)

4 (0–24)

4 (0–24)

5.5 (2–9)

4(0–24)

4 (0–24)

4 (1–9)

Dexamethasone use at discharge

101 (48.6)

63 (54.3)

3 (10)

30 (56.6)

& < 0.001; # < 0.001; §n.s

71 (55.5)

30 (37.5)

0.012

 Mean ± SD dosage (mg)

7.8 ± 6.5

7.2 ± 6.6

7.7 ± 5.1

9.1 ± 6.7

9.2 ± 7.2

4.6 ± 2.3

 Median (Range) dosage (mg)

8 (1–48)

6 (1–48)

9 (2–12)

8(2–24)

8 (2–48)

4 (1–9)

Tumor treatment

 Ongoing tumor spesific therapy at SE admission

61 (29.3)

44 (37.9)

0

15 (28.3)

& < 0.001; #0.001; §n.s

41 (32)

20 (25)

n.s

 Temodal

27 (13.0)

26 (22.4)

0

0

20 (15.6)

7 (8.8)

 CCNU

7 (3.4)

7 (6)

0

0

4 (3.1)

3 (3.8)

 Other chemotherapy

15 (7.2)

3 (2.6)

0

11 (20.8)

9 (7)

6 (7.5)

 Immunotherapy

17 (8.2)

12 (10.3)

0

4 (7.5)

12 (9.4)

5 (6.3)

Tumor treatment prior SE

n.t

n.t

 Neurosurgery

87 (41.8)

39 (33.6)

9 (30)

31 (58.5)

64 (50)

23 (28.8)

 Radiation therapy

117 (56.3)

84 (72.4)

7 (23.3)

23 (43.4)

64 (50)

53 (66.3)

  Radiation

111 (53.4)

84 (72.4)

7 (23.3)

17 (32.1)

62 (48.4)

49 (61.3)

  Gamma knife

7 (3.4)

3 (2.6)

1 (3.3)

13 (24.5)

9 (7)

8 (10)

 Tumor specific therapy

113 (54.3)

67 (57.8)

1 (3.3)

38 (71.7)

69 (53.9)

44 (55)

Radiation therapy < 6 months prior SE

53 (25.5)

43 (37.1)

0

9 (17)

& < 0.001; #0.01; §0.01

32 (25)

21 (26.3)

ns